CSL · 1 day ago
Associate Director, Patient Engagement
King of Prussia, PA
Full-time
Hybrid
Lead/Staff, Director/Executive
10+ years expCSL is a global biotherapeutics leader focused on serving patients' needs through innovative therapies. The Associate Director of Patient Engagement will develop relationships with patient advocacy groups and collaborate on clinical research initiatives to support CSL’s clinical pipeline.
BiotechnologyMedical DeviceHealthcareHealth CareHealth DiagnosticsMedical
Responsibilities
Build and maintain strong relationships with patient advocacy groups, caregivers, and trial participants to inform protocol design and communication strategies
Serve as a strategic advisor to study teams, providing insights into patient needs, site expectations, and regional healthcare dynamics
Lead initiatives to integrate patient engagement into trial planning, recruitment, and retention strategies
Represent CSL in external forums to advocate for patient- and site-centric approaches in clinical research
In collaboration with Site Engagement Leads develop and implement engagement strategies that foster long-term partnerships with clinical trial sites and healthcare institutions
Collaborate cross-functionally with Medical Affairs and external partners to align engagement efforts with portfolio goals
Monitor and analyze trends in site satisfaction and patient engagement to inform continuous improvement
Qualification
Required
Bachelor's Degree in Life Sciences
10+ years' relevant clinical research experience within the pharmaceutical industry
A solid understanding of the drug development process, and specifically, each step within the clinical trial process
Experience in site and patient engagement
Thorough knowledge of ICH guidelines/GCP and its applicability to all stages of the clinical development process
Company
CSL
CSL develops innovative biotherapies and influenza vaccines that save lives, and help people with life-threatening medical conditions.
10001+ employees
Funding
Current Stage
Public CompanyTotal Funding
$111M2013-12-20Acquired
2004-02-06Post Ipo Equity· $111M
1994-06-03IPO
Leadership Team
Jeffrey Ball
Chief Sustainability Officer
Joy Linton
Strategic Advisor
Recent News
Pharma Letter
2026-01-03
2025-10-29
Company data provided by crunchbase